Navigation Links
ThermoGenesis Announces FDA Authorization to Market MarrowXpress(TM) (MXP(TM))
Date:7/14/2008

INITIAL APPLICATION WILL BE FOR USE IN POINT-OF-CARE BONE MARROW PROCESSING

RANCHO CORDOVA, Calif., July 14 /PRNewswire-FirstCall/ -- ThermoGenesis Corp. (Nasdaq: KOOL), a leading supplier of innovative products and services that process and store adult stem cells, today said it has received authorization from the FDA to begin marketing its MarrowXpress (MXP) device for use in a clinical laboratory setting or intraoperatively for preparation of a cell concentrate from bone marrow.

Last month, the Company announced it had submitted a 510(k) pre-market notification application to the FDA. Upon its review, the FDA determined that the device was exempt from the agency's pre-market notification requirements and will instead be regulated as laboratory equipment labeled for a specific medical use. The device is a derivative of the Company's AutoXpress(TM) (AXP(TM)) Platform that is used to volume reduce and collect stem cells from umbilical cord blood.

"This notification that we can immediately begin marketing our MXP device is a major regulatory milestone for the Company and particularly exciting since we received this notification just several weeks after filing our submission, and since it follows by less than a month from having received the CE-Mark enabling us to market the device in the European Community," noted Dr. William Osgood, Chief Executive Officer.

Bone marrow derived stem cells are the dominant source of stem cells studied in regenerative medicine clinical trials for treating several large patient population diseases and injuries including blood disorders, ischemic heart diseases, peripheral artery diseases, and diabetes. According to the latest statistics, there are 24 million people in the U.S. Centers f
'/>"/>

SOURCE ThermoGenesis Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. ThermoGenesis Announces Receipt of CE Mark for MarrowXpress(TM)
2. ThermoGenesis Names Dr. Mahendra Rao to Board of Directors
3. ThermoGenesis Subsidiary Vantus Announces Stem Cell Agreement With UC Davis Center For Equine Health
4. ThermoGenesis Corp. Announces Voluntary Recall of Selected Lots of AXP Bag Sets
5. ThermoGenesis Corp. Reports 48 Percent Growth in Second Quarter Revenues Year Over Year
6. ThermoGenesis Corp. to Announce Second Quarter Fiscal 2008 Results on February 6, 2008
7. ThermoGenesis Corp. to Announce First Quarter Fiscal 2008 Results on November 8, 2007
8. ThermoGenesis Corp. to Present at 2007 Global Life Sciences Conference on Thursday, September 27, 2007
9. ThermoGenesis Corp. Reports Fourth Quarter and Fiscal Year 2007 Results
10. ThermoGenesis Corp. to Announce Fourth Quarter and Year End Results for Fiscal Year 2007 on September 12, 2007
11. NuVasive Announces Web Cast and Conference Call of Second Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... (PRWEB) December 17, 2014 Gene ... that it has entered into a technology access ... (ADM) to apply DNA2.0’s proprietary protein engineering technology, ... process. , “We are extremely excited that the ... platform. This proprietary bioengineering technology has now ...
(Date:12/17/2014)... SOUTH SAN FRANCISCO, Calif. , Dec. 17, ... positive results of a Phase 2 study evaluating ... for the treatment of patients with severe, chronic ... the current standard of care, including topical steroids ... endpoint was percent change in Visual Analog Scale ...
(Date:12/15/2014)...  GlassesOff Inc. (OTCBB: GLSO) announced today the appointment ... director of the Company,s Board of Directors. ... its CEO until its acquisition by Stanley Black ... Recognized as the inventor of the first Wi-Fi-based Active ... -based RFID solutions focused on improving operational efficiency, safety ...
(Date:12/13/2014)... (PRWEB) December 12, 2014 Clarassance, a ... announced its new name: Therabron Therapeutics , Inc. ... and bronchioles (a type of structure in the lungs ... company’s mission to develop novel protein therapeutics for the ... directors decided to change the name to mark the ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2
... Prestwick Pharmaceuticals, Inc., a,privately-held biotechnology company, ... Ph.D. as Executive Vice President, Chief Technology,Officer. ... Prestwick,s pre-clinical,development, regulatory and patent activities around ... candidate, tetrabenazine, a highly,selective and reversible dopamine ...
... of Anesiva,s Needle-Free Technology, SOUTH SAN ... Anesiva, Inc. (Nasdaq: ANSV ) and ... entered into an,agreement granting Particle Therapeutics a ... into its needle-free,intradermal delivery system for glucagon, ...
... Inc.,(Nasdaq: MITI ), a biopharmaceutical company focusing ... cancer, inflammation and,autoimmune diseases, today announced that Dr. ... will present at the Sal. Oppenheim 2nd,European Healthcare ... at 9:50am Eastern time (3:50pm central European time). ...
Cached Biology Technology:Prestwick Pharmaceuticals, Inc. Continues to Build Management Team With Appointment of Martin Stogniew, Ph.D. as Executive Vice President, Chief Technology Officer 2Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug 2Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug 3Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug 4Micromet, Inc. to Present at the Sal. Oppenheim 2nd European Healthcare Conference 2
(Date:12/11/2014)... Minn. , Dec. 10, 2014  Data ... physiologic monitoring, has released a new series of ... of preclinical toxicology researchers. M series, part of ... toxicologists collect the best possible physiologic data when ... Adding functional endpoints to toxicology studies has ...
(Date:12/10/2014)... CIE San Diego has launched an innovative ... tissue that enhances care coordination among social service and ... information; earned a second $1 million grant from the ... aging in community and; will be recognized as a ... 4-6p. CIE San Diego today announced ...
(Date:12/5/2014)... PROVO, Utah , Dec. 4, 2014  Tute ... has raised $2.3 million in Series A1 funding led ... angel investors also participated in the investment round. ... as the healthcare community adopts next-generation sequencing and seeks ... disease," said Reid Robison , MD MBA, and ...
Breaking Biology News(10 mins):New telemetry implants expected to change how large animal toxicology studies are conducted 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 4Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 3
... article in PLoS Medicine, Gert Meijer (University Medical Centre Utrecht, ... has been in restoring the function of diseased or damaged ... authors, the use of bone grafts from a different part ... choice for attempting to restore function. But there are ...
... for the adage, ‘All things in moderation.?Researchers at the University ... high-fat meal are more prone to suffer the physical consequences ... Published this month in the Journal of Nutrition, the study ... one group consumed a fast-food breakfast from McDonald’s, the other ...
... Health have developed an experimental vaccine that reduces stillbirths ... common virus that can also cause mental retardation and ... early fetal life. , Estimates place the number of ... 40,000, and there is no vaccine or treatment for ...
Cached Biology News:A steady, high-fat diet is bad, but the news gets worse 2Experimental vaccine given during pregnancy reduces stillbirths from common virus 2Experimental vaccine given during pregnancy reduces stillbirths from common virus 3
BAI-1 (T-20)...
MOUSE ANTI HUMAN CYTOKERATIN 1-8...
GOAT ANTI HUMAN PSA (ISOFORM 1)...
... peptide derived from the N-terminal region of ... Specificity: Specific for the N-terminus of the ... Dog Rat Mouse (positive controls: MDCK-II A431 ... heart blood vessel and brain mossy fiber ...
Biology Products: